Loading
NASDAQHealthcareBiotechnology
Latest quote
$104.71
+$2.51 · +2.46%
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Previous close
$104.71
+$2.51 · +2.46%
After-hours
$104.71
$0.00 · 0.00%
Sep 11, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Day range
Current $104.71
52-week range
Current $104.71
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
54
Fair Value
Sentiment
67
Bullish
Risk
45
Elevated Risk
Momentum
58
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Day range
Current $104.71
52-week range
Current $104.71
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 189.76M USD | 130.13M USD | 77.43M USD | 23.64M USD | 3.15M USD |
| Cost of goods sold | 19.49M USD | 13.37M USD | 9.3M USD | 2.13M USD | 599K USD |
| Gross profit | 170.27M USD | 116.76M USD | 68.13M USD | 21.51M USD | 2.56M USD |
| Research and development | 167.34M USD | 237.96M USD | 134.95M USD | 108.63M USD | 104.13M USD |
| Selling, general, and administrative | 194.94M USD | 144.3M USD | 117.53M USD | 92.03M USD | 68.49M USD |
| Operating expenses | 362.28M USD | 382.26M USD | 252.48M USD | 200.66M USD | 172.61M USD |
| Interest income | 15.29M USD | 14.71M USD | 13.95M USD | 4.03M USD | 447K USD |
| Interest expense | 20.58M USD | 20.6M USD | 13.89M USD | 5.2M USD | — |
| Depreciation and amortization | 1.34M USD | 1.56M USD | 1.76M USD | 1.67M USD | 1.16M USD |
| Operating income | −192.02M USD | −265.5M USD | −184.36M USD | −179.16M USD | −170.06M USD |
| Net income | −196.54M USD | −260.6M USD | −184.68M USD | −181.12M USD | −69.61M USD |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
